Korsana Biosciences Q3 2026 Results: Net Loss of $46.4M, Loss Widens
Korsana Biosciences completed a reverse recapitalization in 2026, significantly increasing its cash position to $456.2 million through a pre-closing financing. The company reported a net loss of $77.3 million for the nine months ended September 30, 2026, driven primarily by a substantial increase in research and development expenses.
- Key figure
- Net loss $46.4M